Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.
about
Mucinous epithelial cysts of the spleen associated with pseudomyxoma peritonei.Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasmsOvarian cancer developing in the ovarian remnant syndrome. A case report and literature review.Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinomaRecent advances in immunohistochemistry in gynaecological pathology.Keratin expression in human tissues and neoplasms.Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.Metastatic involvement of the spleen by endometrial adenocarcioma; a rare asylum for a common malignancy: a case reportIsolated splenic metastasis of ovaric cancer. Case report and literature reviewMetachronic malignant transformation of small bowel and rectal endometriosis in the same patient.CDX2 as a marker for intestinal differentiation: Its utility and limitations.Herpetiform cutaneous metastases from transitional cell carcinoma of the urinary bladder: immunohistochemical analysis.Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms.Pathology of liver metastases.Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approachThe usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.Immunohistochemistry: A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovaryClinicopathological study of 9 cases of prostate cancer involving the rectal wall.Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma.Quantification of CK20 gene and protein expression in colorectal cancer by RT-PCR and immunohistochemistry reveals inter- and intratumour heterogeneity.PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.Metastases to nasal cavity and paranasal sinuses.Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa.The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.Environmental, dietary, demographic, and activity variables associated with biomarkers of exposure for benzene and lead.Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases.Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1.CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas.
P2860
Q33785777-F570A227-1660-4E68-8066-BE9B655635FAQ33964844-6CF43432-0BB4-40B2-A725-84C7CAD90602Q33990762-400D1D6E-67D7-4C0C-81A3-0B87C2503465Q34391352-9ABA3724-166E-4E1F-8D43-39482FD4F647Q34593864-7F711168-AC7E-4210-942A-0E0EEA17813BQ34636832-3EACA25B-D031-4A8B-A020-DDCF8677C15CQ34790095-5D421DDD-D531-4981-98B7-1D297CCDE2E0Q35046934-9EFED4B1-4220-4A6C-80E6-B5A58C462E25Q35063366-914E0931-D641-4551-9104-E97524225730Q35238222-357DEBFA-EEC7-4694-AE2E-BF34051D8F44Q35618815-02DDD63D-065D-47DD-B987-2DC434EF5353Q35770432-D239D0ED-ECFD-4280-A217-52F0440AE874Q36116519-E608CB8D-8F6E-45A0-BCA0-33CDA5F84F79Q36409942-2482FC38-055C-4BAD-AB63-949863B57AC1Q37080964-52DD45EB-E1F6-4F3E-928D-F8E6CE6B7193Q37236418-5BB27201-BCD7-4E14-A233-188FEB4A4AB9Q37433739-822F0FDC-AC55-43F7-9946-6C94D15C518AQ37463792-D5AB5260-55B7-49D3-B8DD-106A3542DCE2Q37467258-E8773F0F-A715-4EB4-8D0A-CF2EBD80FA42Q37589249-1BE35815-0F08-4E11-942E-567465B02542Q37996298-BA3904AE-9CCE-42CD-B9AA-856070BD7A72Q38283657-A9FC8365-5F34-4E1D-A29D-B4735421DC67Q38455160-6C7DEE80-D08C-4A93-91D9-ACCB15B9746EQ38707402-23971E8C-F75A-45F8-8B91-C57459508EDFQ38842833-EC733B96-8A51-4E72-87F1-0630E4664E27Q41856934-C5C9E747-FA7B-4511-961F-EDF3CBDF86D6Q42536189-A6888FE6-7467-4228-B6C6-1A91027828E6Q44645853-244CA251-6DAD-4CAC-87EA-12A423985A7CQ46145645-63B92ED5-CE61-4180-8AA3-51472A07DC2DQ46461940-283CF29F-3F64-4395-B912-D0BCB77D72F8Q51637566-86985CA2-C40C-40A2-9B01-5FCF8B903D6EQ53489607-84783A60-85C9-49AB-81CB-ABD3E9318DEFQ55250506-3E6E2E81-AF0D-472E-9F92-8CB4C2FB20B0
P2860
Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Tracing the origin of adenocar ...... n carcinomas as primary sites.
@en
Tracing the origin of adenocar ...... n carcinomas as primary sites.
@nl
type
label
Tracing the origin of adenocar ...... n carcinomas as primary sites.
@en
Tracing the origin of adenocar ...... n carcinomas as primary sites.
@nl
prefLabel
Tracing the origin of adenocar ...... n carcinomas as primary sites.
@en
Tracing the origin of adenocar ...... n carcinomas as primary sites.
@nl
P2093
P1433
P1476
Tracing the origin of adenocar ...... n carcinomas as primary sites.
@en
P2093
C J Meijer
G A Meijer
J H Lagendijk
P J Van Diest
P304
P356
10.1016/S0046-8177(98)90065-X
P407
P577
1998-05-01T00:00:00Z